Nick Leschly (Credit: Jeff Rumans at Endpoints News JPM20)
February 16, 2021 07:52 AM ESTUpdated 01:04 PM
R&D
Cell/Gene Tx

Blue­bird hits the brakes on Lenti­Glo­bin stud­ies, Zyn­te­glo mar­ket­ing af­ter AML, myelodys­plas­tic syn­drome cas­es spur fresh safe­ty con­cerns

John Carroll

Editor & Founder

Blue­bird bio $BLUE has run in­to a fresh set of trou­bles for its gene ther­a­py Lenti­Glo­bin.

The biotech, which has seen its gene ther­a­py work …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bris­tol My­ers CEO sig­nals deal­mak­ing will be a top pri­or­i­ty in 2025

Drug­mak­ers see a sub­stan­tial, but man­age­able, hit to busi­ness from tar­iffs. But the worst may lie ahead

Roche CEO warns that tar­iffs could im­pact deal­mak­ing

Ver­san­t's lat­est biotech fo­cus­es on in­flam­ma­to­ry dis­eases

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times